- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04083950
경구 백신에 의한 장 투과성 유도
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.
연구 개요
상태
상세 설명
The licensed Ty21a vaccine strain of S. enterica Typhi is routinely used by travelers to countries where typhoid is common. It is not known whether the vaccine causes measurable changes in intestinal permeability and whether changes in permeability are correlated with the magnitude of the vaccine response. In the current study, gut permeability will be measured in participants at baseline and after an aspirin challenge, which is known to disrupt intestinal permeability, and after the first, second, and fourth doses of a the Ty21a vaccine. Intestinal permeability will be measured using a three-sugar absorption test composed of lactulose, mannitol, and sucralose and by several plasma markers. Vaccine response will be measured by quantitating T cells and newly developed IgG-or IgA-secreting plasma cells specific for Ty21a.
연구 유형
등록 (실제)
단계
- 초기 1단계
연락처 및 위치
연구 장소
-
-
California
-
Davis, California, 미국, 95616
- USDA, ARS, Western Human Nutrition Research Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Body Mass Index (BMI) 18.5 - 29.9 kg/m2
Exclusion Criteria:
- Has HIV/AIDS or another disease that affects the immune system
- Has any kind of cancer
- Decline to take an HIV blood test
- Blood pressure greater than or equal to 140/90 mmhg
- Pregnant or lactating women
- Refusal to take a pregnancy test prior to the study
- Refusal to use a method of birth control during the study
- Allergy to vaccine components, i.e. Thimerosal and enteric-coated capsules
- Allergy to oral typhoid vaccine
- Allergy to aspirin
- Daily use of blood thinners
- Use of anti-inflammatory medications, i.e. nonsteroidal anti-inflammatory drugs (NSAID), aspirin, 3 or more times per month
- Use of sulfonamides or antibiotics in the past 30 days
- Use of anti-hypertensive drugs, i.e. beta blockers, diuretics, calcium channel blockers
- Use of anti-malaria drugs, i.e. Mefloquine, chloroquine, and proguanil
- Use of drugs that affect the immune system, i.e. immunosuppressants, immune-modifying drugs, corticosteroids, i.e. cortisone, prednisone, methylprednisolone, for 2 weeks or longer
- Is taking cancer treatment with radiation or drugs
- Greater than ten years residence in a typhoid-endemic area
- Receipt of typhoid vaccine in the last 5 years
- Receipt of any vaccine two weeks prior to receipt of Ty21a vaccine
- Individuals at increased risk of developing complications from a live, bacterial vaccine
- History of typhoid fever
- History of primary immune deficiency or autoimmune disease
- History of acute or chronic gastrointestinal (GI) disorder, i.e. Crohn's disease, irritable bowel syndrome, gastric ulcer
- Diarrheal illness (defined as passing 3 or more abnormally loose or watery stool in a 24 hour period) or persistent vomiting 2 weeks prior to the study
- History of bleeding disorder, including bleeding from the GI tract
- History of chronic illnesses, i.e. diabetes, cardiovascular disease, cancer, gastrointestinal malabsorption or inflammatory diseases, kidney disease, autoimmune disorders, HIV, liver disease, including hepatitis B and C.
- Asthma if taking medication on a daily basis
- Recent surgery (within 3 months)
- History of GI surgery
- Recent hospitalization (within 3 months)
- Acute febrile illness (within 2 weeks)
- Unwillingness to discontinue consumption of artificial sweeteners in foods or drinks, i.e. sport drinks, coconut water, "diet" drinks and foods (possibly containing sucralose)
- Not having at least one arm vein suitable for blood drawing
- Unwilling or uncomfortable with blood draws seven times in 29 days
- Regular blood or blood product donation and refusal to suspend donation
- Current participation in another research study
- Unable to fast for 12-16 hours
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Single group
All participants will receive the vaccine and aspirin. |
One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
다른 이름들:
Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in intestinal permeability
기간: Day 1, 3, 16, 18, and 22
|
Measurement of sugar (lactulose, D-mannitol, and sucralose) excretion in urine. |
Day 1, 3, 16, 18, and 22
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Antibody response to typhoid vaccination
기간: Day 1, 18, 22, 24, and 29
|
Measurement of Typhi-specific immunoglobulin G (IgG) and immunoglobulin A (IgA) plasma cells in peripheral blood using the antibody in lymphocyte supernatant assay. |
Day 1, 18, 22, 24, and 29
|
|
T-cell response to typhoid vaccination
기간: Day 1, 22, and 29
|
Measurement of vaccine-specific cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cells in peripheral blood mononuclear cells. |
Day 1, 22, and 29
|
|
Change in markers of inflammation
기간: Day 1, 3, 16, 18, 22, and 24
|
Measurement of plasma cytokines, chemokines, and acute phase proteins by a multiplex immunoassay. |
Day 1, 3, 16, 18, 22, and 24
|
|
Change in intestinal fatty acid binding protein (iFABP)
기간: Day 1, 3, 16, 18, and 22
|
Measurement of plasma iFABP. |
Day 1, 3, 16, 18, and 22
|
|
Change in D-lactate
기간: Day 1, 3, 16, 18, and 22
|
Measurement of plasma D-lactate. |
Day 1, 3, 16, 18, and 22
|
|
Change in diamine oxidase
기간: Day 1, 3, 16, 18, and 22
|
Measurement of plasma diamine oxidase. |
Day 1, 3, 16, 18, and 22
|
|
Change in lipopolysaccharide binding protein (LBP)
기간: Day 1, 3, 16, 18, and 22
|
Measurement of plasma LBP. |
Day 1, 3, 16, 18, and 22
|
|
Change in citrulline
기간: Day 1, 3, 16, 18, and 22
|
Measurement of plasma citrulline. |
Day 1, 3, 16, 18, and 22
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Danielle Lemay, PhD, USDA, ARS, Western Human Nutrition Research Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- FL109
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .